Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor necrosis factor-related apoptosis-inducing ligand mRNA
- Development stage
- Preclinical
- Lead developer
- University of Alberta
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mRNA is an mRNA-based therapeutic designed to induce apoptosis in cancer cells, specifically non-small cell lung cancer (NSCLC). TRAIL is a cytokine that binds to death receptors (DR4 and DR5), triggering the extrinsic apoptotic pathway and subsequent caspase activation. While recombinant TRAIL protein has faced challenges due to rapid clearance and resistance, delivery via mRNA allows for sustained intracellular production of the ligand. In preclinical studies conducted at the University of Alberta, TRAIL mRNA was encapsulated in biodegradable cationic lipopolymers to form nanoparticles. This approach has shown efficacy in reducing viability and inducing mitochondrial depolarization and DNA damage in various NSCLC cell lines, particularly when combined with siRNAs targeting anti-apoptotic mediators to overcome resistance.
- Other names
- tumor necrosis factor-related apoptosis-inducing ligand messenger RNATNFSF10 mRNATNFSF-10 mRNATNFSF 10 mRNA
02
Targets
TNFRSF10B (DR5)TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on tumor necrosis factor-related apoptosis-inducing ligand mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor necrosis factor-related apoptosis-inducing ligand mRNA.